Trinity Biotech (TRIB) Long-Term Deferred Tax (2009 - 2025)

Trinity Biotech (TRIB) has reported Long-Term Deferred Tax for 17 consecutive years, with $105.2 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 1.82% year-over-year to $105.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $105.2 million (up 1.82% YoY) and the FY2025 annual result came in at $105.2 million, up 1.82% from the prior year.
• Long-Term Deferred Tax improved to $105.2 million in Q4 2025 per TRIB's latest filing, from $3.5 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for TRIB reached as high as $105.2 million in Q4 2025 and fell as low as $694000.0 in Q3 2024.
• A 5-year average of $14.4 million and a median of $3.9 million in 2021 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax sank 75.29% — and 2024, when it soared 5129.87%.
• Year by year, Long-Term Deferred Tax stood at $4.1 million in 2021, then grew by 2.85% to $4.2 million in 2022, then sank by 53.18% to $2.0 million in 2023, then surged by 5129.87% to $103.3 million in 2024, then advanced by 1.82% to $105.2 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $105.2 million, $3.5 million, and $103.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.